70 related articles for article (PubMed ID: 9220975)
1. Alteration of substrate specificity by mutations at the His61 position in predicted transmembrane domain 1 of human MDR1/P-glycoprotein.
Taguchi Y; Kino K; Morishima M; Komano T; Kane SE; Ueda K
Biochemistry; 1997 Jul; 36(29):8883-9. PubMed ID: 9220975
[TBL] [Abstract][Full Text] [Related]
2. Amino acid substitutions in the first transmembrane domain (TM1) of P-glycoprotein that alter substrate specificity.
Taguchi Y; Morishima M; Komano T; Ueda K
FEBS Lett; 1997 Aug; 413(1):142-6. PubMed ID: 9287132
[TBL] [Abstract][Full Text] [Related]
3. Selective modulation of P-glycoprotein-mediated drug resistance.
Bebawy M; Morris MB; Roufogalis BD
Br J Cancer; 2001 Dec; 85(12):1998-2003. PubMed ID: 11747345
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of P-glycoprotein and multidrug resistance protein 1 by dietary phytochemicals.
Nabekura T; Yamaki T; Ueno K; Kitagawa S
Cancer Chemother Pharmacol; 2008 Oct; 62(5):867-73. PubMed ID: 18204840
[TBL] [Abstract][Full Text] [Related]
5. Drug resistance induced by ouabain via the stimulation of MDR1 gene expression in human carcinomatous pulmonary cells.
Brouillard F; Tondelier D; Edelman A; Baudouin-Legros M
Cancer Res; 2001 Feb; 61(4):1693-8. PubMed ID: 11245485
[TBL] [Abstract][Full Text] [Related]
6. Improved energy coupling of human P-glycoprotein by the glycine 185 to valine mutation.
Omote H; Figler RA; Polar MK; Al-Shawi MK
Biochemistry; 2004 Apr; 43(13):3917-28. PubMed ID: 15049699
[TBL] [Abstract][Full Text] [Related]
7. Induction of multidrug resistance in MOLT-4 cells by anticancer agents is closely related to increased expression of functional P-glycoprotein and MDR1 mRNA.
Liu ZL; Onda K; Tanaka S; Toma T; Hirano T; Oka K
Cancer Chemother Pharmacol; 2002 May; 49(5):391-7. PubMed ID: 11976833
[TBL] [Abstract][Full Text] [Related]
8. Extent of the selectivity filter conferred by the sixth transmembrane region in the CFTR chloride channel pore.
Gupta J; Lindsell P
Mol Membr Biol; 2003; 20(1):45-52. PubMed ID: 12745925
[TBL] [Abstract][Full Text] [Related]
9. Characterization of rhodamine 123 binding to P-glycoprotein in human multidrug-resistant cells.
Nare B; Prichard RK; Georges E
Mol Pharmacol; 1994 Jun; 45(6):1145-52. PubMed ID: 7912815
[TBL] [Abstract][Full Text] [Related]
10. Transmembrane segment 7 of human P-glycoprotein forms part of the drug-binding pocket.
Loo TW; Bartlett MC; Clarke DM
Biochem J; 2006 Oct; 399(2):351-9. PubMed ID: 16813563
[TBL] [Abstract][Full Text] [Related]
11. Multidrug resistance in androgen-independent growing rat prostate carcinoma cells is mediated by P-glycoprotein.
Siegsmund MJ; Kreukler C; Steidler A; Nebe T; Köhrmann KU; Alken P
Urol Res; 1997; 25(1):35-41. PubMed ID: 9079744
[TBL] [Abstract][Full Text] [Related]
12. Pervilleine A, a novel tropane alkaloid that reverses the multidrug-resistance phenotype.
Mi Q; Cui B; Silva GL; Lantvit D; Lim E; Chai H; You M; Hollingshead MG; Mayo JG; Kinghorn AD; Pezzuto JM
Cancer Res; 2001 May; 61(10):4030-7. PubMed ID: 11358822
[TBL] [Abstract][Full Text] [Related]
13. Inhibitory effect of the reversal agents V-104, GF120918 and Pluronic L61 on MDR1 Pgp-, MRP1- and MRP2-mediated transport.
Evers R; Kool M; Smith AJ; van Deemter L; de Haas M; Borst P
Br J Cancer; 2000 Aug; 83(3):366-74. PubMed ID: 10917553
[TBL] [Abstract][Full Text] [Related]
14. Reversal of p-glycoprotein-mediated multidrug resistance by macrocyclic bisbibenzyl derivatives in adriamycin-resistant human myelogenous leukemia (K562/A02) cells.
Li X; Sun B; Zhu CJ; Yuan HQ; Shi YQ; Gao J; Li SJ; Lou HX
Toxicol In Vitro; 2009 Feb; 23(1):29-36. PubMed ID: 18938236
[TBL] [Abstract][Full Text] [Related]
15. Levels of multidrug resistance (MDR1) P-glycoprotein expression by human breast cancer correlate with in vitro resistance to taxol and doxorubicin.
Mechetner E; Kyshtoobayeva A; Zonis S; Kim H; Stroup R; Garcia R; Parker RJ; Fruehauf JP
Clin Cancer Res; 1998 Feb; 4(2):389-98. PubMed ID: 9516927
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of P-glycoprotein transport function and reversion of MDR1 multidrug resistance by cnidiadin.
Barthomeuf C; Grassi J; Demeule M; Fournier C; Boivin D; Béliveau R
Cancer Chemother Pharmacol; 2005 Aug; 56(2):173-81. PubMed ID: 15824923
[TBL] [Abstract][Full Text] [Related]
17. Levistolide A overcomes P-glycoprotein-mediated drug resistance in human breast carcinoma cells.
Chen F; Wang T; Wang J; Wang ZQ; Qian M
Acta Pharmacol Sin; 2008 Apr; 29(4):458-64. PubMed ID: 18358092
[TBL] [Abstract][Full Text] [Related]
18. Reduced drug resistance in a multidrug resistant cell line by 5,8,11,14-eicosatetraynoic acid.
Anderson KM; Harris JE
Res Commun Mol Pathol Pharmacol; 1994 Nov; 86(2):195-203. PubMed ID: 7881868
[TBL] [Abstract][Full Text] [Related]
19. Quinoline derivative KB3-1 potentiates paclitaxel induced cytotoxicity and cycle arrest via multidrug resistance reversal in MES-SA/DX5 cancer cells.
Koo JS; Choi WC; Rhee YH; Lee HJ; Lee EO; Ahn KS; Bae HS; Ahn KS; Kang JM; Choi SU; Kim MO; Lu J; Kim SH
Life Sci; 2008 Nov; 83(21-22):700-8. PubMed ID: 18845169
[TBL] [Abstract][Full Text] [Related]
20. Reversing drug resistance in the ovarian carcinoma cell line SKOV3/mdr1 in vitro by antisense oligodeoxynucleotides.
Pan L; Tong Y; Jin Y; Zhou S; Zhang Y; Yang X; Mao N
Chin Med J (Engl); 2001 Sep; 114(9):929-32. PubMed ID: 11780384
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
